Overview

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Phase:

Phase 4

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Treatments:

Angiotensin-Converting Enzyme Inhibitors
Hydrochlorothiazide
Olmesartan
Olmesartan Medoxomil